John David Chetwood
Overview
Explore the profile of John David Chetwood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chetwood J, Paramsothy S, Leong R
Am J Gastroenterol
. 2025 Jan;
PMID: 39787365
Background/aims: There are spare data on comparative medication efficacy in fistulizing Crohn's disease (FCD), particularly with immunomodulator co-therapy. Persistence is a unique way to assess real-world outcomes. Methods: The persistence...
2.
Lee T, Ding N, Chetwood J
Aliment Pharmacol Ther
. 2025 Jan;
61(4):739-740.
PMID: 39744874
No abstract available.
3.
Schildkraut T, Ding N, Chetwood J
Aliment Pharmacol Ther
. 2024 Nov;
61(1):234-235.
PMID: 39533664
No abstract available.
4.
Leong R, Sakiris A, Arzivian A, Chetwood J, Chaemsupaphan T, Sparrow M, et al.
Aliment Pharmacol Ther
. 2024 Oct;
61(1):132-144.
PMID: 39387155
Background: Given the introduction of new advanced therapies for inflammatory bowel diseases (IBDs), expanded risk mitigation strategies are essential. Aims: To create a comprehensive set of statements on assessment procedures...
5.
Chetwood J, Ding N
Aliment Pharmacol Ther
. 2024 Sep;
60(10):1479-1480.
PMID: 39295271
No abstract available.
6.
Chetwood J, Arzivian A, Shin J, Tamilarasan A
Clin Case Rep
. 2024 Aug;
12(8):e9314.
PMID: 39165494
Metastatic Crohn's disease is the rarest cutaneous manifestation of Crohn's disease, it presents as cutaneous lesions in areas that are anatomically non-contiguous with the gastrointestinal tract. It requires a high...
7.
Chetwood J, Tran Y, Subramanian S, Smith P, Iborra M, Buisson A, et al.
J Crohns Colitis
. 2024 Apr;
18(9):1440-1449.
PMID: 38656784
Background: Subcutaneous [SC] infliximab may provide multiple benefits over intravenous [IV] formulations. However, studies for efficacy and safety in inflammatory bowel disease [IBD] have been constrained by small sizes that...
8.
Chetwood J, Ko Y, Pudipeddi A, Kariyawasam V, Paramsothy S, Leong R
Am J Gastroenterol
. 2024 Jan;
119(8):1536-1544.
PMID: 38275272
Introduction: Comparative effectiveness research provides data on the relative benefits and risks between treatments. In Crohn's disease (CD), however, there are few head-to-head studies comparing advanced therapies and none with...
9.
Chetwood J, Paramsothy S, Haifer C, Borody T, Kamm M, Leong R, et al.
Gut
. 2023 Aug;
73(8):1392-1393.
PMID: 37591699
No abstract available.
10.
Chetwood J, Sabih A, Chan K, Salimi S, Sheiban A, Lin E, et al.
J Gastroenterol Hepatol
. 2023 Apr;
38(8):1325-1332.
PMID: 37096760
Background And Aim: Acute-on-chronic liver failure (ACLF) is distinct from acute decompensation (AD) of cirrhosis in its clinical presentation, pathophysiology, and prognosis. There are limited published Australian ACLF data. Methods:...